Ironwood Pharmaceuticals, Inc. / Fundamentals
Income statement
- Net revenue
€264.12M - Cost of goods sold
€815.00K - Gross profit
€263.31M - SG&A expenses
€94.82M - R&D expenses
€90.77M - EBITDA
€67.90M - D&A
€1.66M - EBIT
€64.33M - Interest expenses
€29.76M - EBT
€36.74M - Tax expenses
€43.62M - Net income
-€5.95M
Cash flow statement
- Net deferred tax
€54.41M - Non-cash items
€2.21M - Changes in working capital
-€45.31M - Operating cash flow
€25.67M - Capex
€41.95K - Other investing cash flow
€0.00 - Net investing cash flow
-€55.65K - Total cash dividends paid
€0.00 - Issuance of common stock
€0.00 - Debt repayment
-€32.40M - Other financing cash flow
-€1.67M - Net financing cash flow
-€35.91M - Foreign exchange effects
-€564.16K - Net change in cash
-€10.85M - Cash at end of period
€79.49M - Free cash flow
€25.71M
Balance sheet
- Cash and cash equivalents
€79.49M - Cash and short-term investments
€79.49M - Total receivables
€73.77M - Inventory
€0.00 - Other current assets
€10.90M - Total current assets
€164.16M - Property, plant & equipment
€12.10M - Goodwill
€0.00 - Intangible assets
€2.10M - Long-term investments
€0.00 - Other non-current assets
€4.41M - Total non-current assets
€129.43M - Total assets
€293.59M - Accounts payable
€1.19M - Short-term debt
€173.40M - Other current liabilities
€24.47M - Total current liabilities
€199.06M - Long-term debt
€339.11M - Deferred tax liabilities
€0.00 - Other non-current liabilities
€19.23M - Total non-current liabilities
€358.35M - Total liabilities
€379.23M - Common stock
€0.00 - Retained earnings
€0.00 - Other equity
€0.00 - Total equity
-€85.63M - Total liabilities and shareholders' equity
€293.59M
Company information
- Market capitalization
€100.88M - Employees
253 - Enterprise Value
€607.39M
Company ratios
- Gross margin
-
99.7% Much better than peer group: -7,162.2% - EBITDA margin
-
25.7% Much worse than peer group: 986,371.3% - EBIT margin
-
24.4% Much worse than peer group: 926,405.1% - EBT margin
-
13.9% Much worse than peer group: 987,042.7% - Net margin
-
-2.3% Much worse than peer group: 893,733.6% - ROE
-
7.0% Much better than peer group: -19.7% - ROA
-
-2.0% Much better than peer group: -20,982.7% - Asset turnover
-
90.0% Much worse than peer group: 5,890.4% - FCF margin
-
9.7% Much worse than peer group: 691,415.6% - FCF yield
25.4% - Efficiency ratio
74.3% - Net sales per employee
-
€1.04M - Net income per employee
-
-€23.52K